WallStSmart

Evolus Inc (EOLS)vsViatris Inc (VTRS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Viatris Inc generates 4712% more annual revenue ($14.30B vs $297.18M). EOLS leads profitability with a -17.4% profit margin vs -24.6%. VTRS earns a higher WallStSmart Score of 50/100 (C-).

EOLS

Avoid

32

out of 100

Grade: F

Growth: 6.7Profit: 2.0Value: 5.0Quality: 5.0

VTRS

Buy

50

out of 100

Grade: C-

Growth: 3.3Profit: 3.5Value: 6.7Quality: 5.5
Piotroski: 4/9Altman Z: 0.80

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EOLS0 strengths · Avg: 0/10

No standout strengths identified

VTRS2 strengths · Avg: 10.0/10
PEG RatioValuation
0.1410/10

Growing faster than its price suggests

Price/BookValuation
1.1x10/10

Reasonable price relative to book value

Areas to Watch

EOLS4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$301.88M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-187.3%2/10

ROE of -187.3% — below average capital efficiency

Profit MarginProfitability
-17.4%1/10

Currently unprofitable

VTRS4 concerns · Avg: 1.8/10
Return on EquityProfitability
-21.1%2/10

ROE of -21.1% — below average capital efficiency

EPS GrowthGrowth
-70.6%2/10

Earnings declined 70.6%

Altman Z-ScoreHealth
0.802/10

Distress zone — elevated risk

Profit MarginProfitability
-24.6%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : EOLS

Revenue growth of 14.4% demonstrates continued momentum.

Bull Case : VTRS

The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.14 suggests the stock is reasonably priced for its growth.

Bear Case : EOLS

The primary concerns for EOLS are EPS Growth, Market Cap, Return on Equity.

Bear Case : VTRS

The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.

Key Dynamics to Monitor

EOLS carries more volatility with a beta of 1.01 — expect wider price swings.

EOLS is growing revenue faster at 14.4% — sustainability is the question.

VTRS generates stronger free cash flow (551M), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.

Bottom Line

VTRS scores higher overall (50/100 vs 32/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Evolus Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Evolus, Inc., a high-performance beauty company, provides aesthetic medical products for physicians and their patients in the United States. The company is headquartered in Newport Beach, California.

Viatris Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.

Visit Website →

Want to dig deeper into these stocks?